Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 3/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
| ▸ | CLK1 | P49759 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563425 | 0.95 | KDM4E (0.45) | CACNA1HCACNA1BCLK1KDM4EALDH1A1 | |
| SCHEMBL5558726 | 0.89 | CLK1 (0.47) | CLK1MAPK9MAPK14DYRK1A | |
| SCHEMBL5564638 | 0.89 | CLK1 (0.45) | CLK1MAPK9MAPK14DYRK1A | |
| SCHEMBL5565157 | 0.88 | MCHR1 (0.46) | CLK1MAPK9MAPK14 | |
| SCHEMBL5563584 | 0.85 | CLK1 (0.45) | CLK1MAPK9MAPK14DYRK1A | |
| SCHEMBL5563787 | 0.84 | CLK1 (0.41) | CLK1MAPK9MAPK14 | |
| SCHEMBL5564800 | 0.81 | HDAC1 (0.47) | ALDH1A1PDGFRBPDGFRAMAPK9MAPK14 | |
| SCHEMBL5565342 | 0.81 | CLK1 (0.46) | CLK1MAPK14SMN1; SMN2 | |
| SCHEMBL5558120 | 0.79 | CLK1 (0.48) | CLK1MAPK14DYRK1A | |
| SCHEMBL5564923 | 0.76 | TBXAS1 (0.56) | CLK1KDM4EALDH1A1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208491-B2 | N-monoacylated o-phenylenediamines | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1594857-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069133-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI -CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HOFFMANN-LA ROCHE INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HDAC1, HDAC11, HDAC7 | CACNA1H 4290/4885CACNA1B 4495/4885CLK1 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.